An open label randomised comparative clinical trial to evaluate the efficacy of Priyangu Ghana Satva and Lajjalu Ghana Satva along with Sadyovirechan in the management of Asrigdara (Abnormal Uterine Bleeding O and E)

Abnormal Uterine Bleeding is defined as bleeding from the uterine corpus which is abnormal in duration, volume, frequency and/or regularity. In Ayurveda, due to similarity in symptoms it can be correlated with Asrigdara which is defined as excessive or prolonged blood loss during menstruation with or without intermenstrual bleeding.To evaluate and compare the efficacy of Priyangu Ghana Satva and Lajjalu Ghana.Satva along with Sadyovirechan in normalization of menstrual flow.The trail will be performed in two groups consisting 30 in each group.One group will be given Priyangu Ghana Satva along with Sadyovirechana and the second group will receive Lajjalu Ghana Satva along with Sadyovirechana.The inclusion criteria is Subjects having confirm diagnosis of Asrigdara (Abnormal uterine bleeding O and E), Married and Unmarried Subjects of age group between 20 to 40 years who are willingto take part in the study Informed and written consent.Subjects presenting with at least one of the following features will be included in the study: Excessive Bleeding or Prolonged Bleeding and exclusion criteria is AUB P Polyp AUB A Adenomyosis AUB L Leiomyoma AUB M Malignancy AUB C Confirmed Coagulopathy AUB I Iatrogenic Cause Endometrial Hyperplasia ET more than 11 mm Bleeding due to cervical erosion CA cervix Bleeding following abortion Bleeding due to IUCD Bleeding from any site other than uterus PID Pregnancy Uncontrolled Hypothyroidism Hyperthyroidism Patient taking ATT Endometriosis Diabetes mellitus Hypertension Post-menopausal bleeding Hb less than 8gm. The primary expected outcome are decrease in Amount of Blood Flow and Decrease in Duration of Blood Flow.Secondary Expected Outcome are Reduction in Pain and Increase in Hb% by 1-2%